MILL VALLEY, Calif./PRNewswire/ -- Collaborative Medicinal Development LLC ("CMD"), a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases, reported promising results from its phase 1 dose-finding study of CuATSM for treatment of ALS at the 29th International Symposium on ALS/MND held in Glasgow, Scotland from December 7-9, 2018. In a presentation, Dr. Craig Rosenfeld, CMD's CEO, reported that over 24 weeks treatment at the recommended phase 2 dose, evaluable patients with sporadic ALS showed a dramatic slowing in disease progression by ALSFRS-R score (-0.29 points/month compared with an expected -1.02 points/month), an improvement in respiratory function by FVC (+1.1 % predicted/month compared with an expected -2.24 % predicted/month), and improvement in cognitive function by ECAS score (+10 points over 24 weeks compared with no change expected). At lower CuATSM dose levels, evaluable patients showed expected decreases in ALSFRS-R score and FVC over 24 weeks, providing a dramatic dose-response effect previously observed in ALS mouse models. CMD plans to initiate a randomized, placebo-controlled study of CuATSM in ALS to confirm the promising results seen in the open-label phase 1 study.
About Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressive and fatal neurodegenerative disease characterized by muscle weakness resulting from degeneration of motor neurons. Patients usually die of respiratory failure within 2 to 3 years of symptoms onset. There is an urgent unmet medical need for disease modifying therapies in ALS. Further information about ALS is available at https://fightmnd.com/
For further Information
Rory Hill, Business Development